Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jodi Bradley"'
Autor:
Dawn Weishuhn, Simone Brioschi, Diana Cha, Marco Colonna, Daniel Yoo, Sara Rao, Samuel A. Hasson, Jodi Bradley, Peng Luan, Ian Foltz, Shilpa Sambashivan, Shoutang Wang, Daniel C. Ellwanger, Menno Van Lookeren Campagne, Susan Gilfillan, Palaniswami Rathanaswami, Ryan Case, Lydia Green, Zhifei Shao
Publikováno v:
Proc Natl Acad Sci U S A
Triggering receptor expressed on myeloid cells 2 (TREM2) sustains microglia response to brain injury stimuli including apoptotic cells, myelin damage, and amyloid β (Aβ). Alzheimer’s disease (AD) risk is associated with the TREM2(R47H) variant, w
Autor:
Paul H. Wen, Stephen J. Wood, Qingyian Liu, Aaron C. Siegmund, Liping H. Pettus, Adrian Nanez, Matthew P. Bourbeau, Jennifer R. Allen, Michael D. Bartberger, Douglas A. Whittington, Jodi Bradley, James R. Manning, Kui Chen, Dean Hickman, Michael E. Johnson
Publikováno v:
Journal of medicinal chemistry. 63(5)
β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) is an aspartyl protease that plays a key role in the production of amyloid β (Aβ) in the brain and has been extensively pursued as a target for the treatment of Alzheimer's disease (AD). B
Autor:
Ai-Ching Lim, Jean Danao, Nikolai A. Sharkov, Steve Thibault, Songli Wang, Steve Wood, Edoardo Marcora, Santosh Talreja, Eric Bragg, Zhongqi Zhang, Jason Richardson, Ian Foltz, Rob Kegel, Hang Chen, Jodi Bradley, Xiaoshan Min, Shilpa Sambashivan, Zhulun Wang, Athena Sudom
Triggering receptor expressed on myeloid cells 2 (TREM2) is an immune receptor expressed on the surface of microglia, macrophages, dendritic cells, and osteoclasts. The R47H TREM2 variant is a significant risk factor for late-onset Alzheimer's diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeef296643aab8b942f16b84784bc212
https://europepmc.org/articles/PMC6093241/
https://europepmc.org/articles/PMC6093241/
Autor:
Qingyian Liu, Kaustav Biswas, Frank Koegler, Tiffany L. Correll, Toni Williamson, Jodi Bradley, Jennifer R. Allen, Leeanne Zalameda, Darren L. Reid, Michael D. Bartberger, Joe Zhu, Stephen J. Wood, Randy Hungate, Yichin Liu, Frank Chavez, Robert M. Rzasa, Jianhua Zhang, John D. McCarter, Thomas Nixey, Paul H. Wen, Li Zhu, Shannon Rumfelt, Yi Luo, Safura Babu-Khan, Stephen Hitchcock, Ning Chen, Mqhele Ncube, Wenyuan Qian, Frenel Fils Demorin, Dean Hickman, Christopher M. Tegley, Jian J. Chen, Albert Amegadzie, Charles W. Dean, Chester Chenguang Yuan
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 23:6447-6454
γ-Secretase modulators (GSMs) are potentially disease-modifying treatments for Alzheimer's disease. They selectively lower pathogenic Aβ42 levels by shifting the enzyme cleavage sites without inhibiting γ-secretase activity, possibly avoiding know
Autor:
Yi Luo, Matthew Weiss, Stephen J. Wood, Tom Dineen, Kui Chen, Jodi Bradley, Hongbing Huang, Ted Judd, Patricia Lopez, Li Zhu, Yuan Cheng, Patricia Amarante, Dean Hickman, Bryant Yang, Paul Acton, Safura Babu-Khan, Steven W. Louie, Mathew Kaller, Joel Esmay, Jan Zhang, Russell Graceffa, Wenge Zhong, Daniel B. Horne, Toni Williamson, Paul H. Wen, Robert C. Wahl
Publikováno v:
Alzheimer's & Dementia. 8